A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Bazlitoran (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIONEER
- Sponsors Idera Pharmaceuticals
- 24 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 12 Jun 2018 Results published in an Idera Pharmaceuticals Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History